A Phase 2 interventional study of Orticumab and Placebo in Psoriasis, Inflammation and Coronary Artery Disease, sponsored by Abcentra. Completed at 13 sites in United States. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Abcentra · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.
Among the 764 studies in Psoriasis with a site in United States, this one is the 337th largest by enrollment of the 673 interventional ones that give a count, is one of 38 that started in 2021, is one of 200 in phase 2, and was the 612th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
InventisBio Co., Ltd · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
764 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 38 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is close to the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 673 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 375 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
524 of 764 have an industry lead sponsor. The 10 most frequent:
Abcentra is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Abcentra has 1 study filed under Psoriasis — fewer than ten, so there is no comparison to draw.
22 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 764 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this proof-of-activity, phase 2 trial is to evaluate the safety and activity of orticumab in subjects with moderate to severe psoriasis and cardiometabolic risk factors.
This randomized, double-blind, study is designed to compare the effect of orticumab against placebo in subjects with moderate to severe psoriasis and cardiometabolic risk factors. A total of 75 subjects will be randomized in a double-blind fashion to receive intravenous (IV) infusions either of orticumab or placebo for up to 78 days.
Participants will be enrolled into one of the two groups: active treatment or placebo. Subjects will be randomized in a 2:1 ratio, orticumab to placebo and receive up to 11 weeks of treatment.
Planned treatments are weekly x 4 , then monthly x 2 . The Internal Safety Review Committee (ISRC) will review the blinded safety data after the first subject completes the first dose (Day 1), the first five subjects complete the first dose (Day 1), and the first ten subjects complete the first dose (Day 1). The IRSC will review all adverse reactions to all administered doses at these times.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects are excluded from the study if any of the following criteria are met:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes. Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months.
Drug: Orticumab
Dosage: Repeating intravenous dose. Administered by infusion over 30 minutes. Frequency and duration: once weekly x 4 weeks, then once monthly x 2 months.
Drug: Placebo
A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
Also known as: MLDL1278a; BI-204; Anti-oxLDL Antibody
Placebo for orticumab, containing all components of formulation except the active ingredient
Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)
PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)
Time frame: 106 days (Week 15)
Percentage of Participants Achieving Treatment Success by the 5-point Static Investigator's Global Assessment Modified 2011 Version (sIGA) Score
Percentage of participants achieving treatment success (clear =0 or almost clear =1) and greater than or equal to (\>=) 2 Point Improvement at Week 15 on the sIGA scale
Time frame: 106 days (Week 15)
Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI)
PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)
Time frame: Weeks 1, 3, 7, and 11
Percentage of Participants Achieving PASI75 and PASI50
PASI75 is a 75 percent reduction in PASI score. PASI50 is a 50 percent reduction in PASI score
Time frame: Weeks 1, 3, 7, and 11
Mean Percent Change in Baseline in Body Surface Area (BSA) % Involvement
Minimum: 0 percent, Maximum: 100 percent. Higher percentage indicates more skin with psoriasis.
Time frame: Weeks 1, 3, 7, 11, 15
Mean Change From Baseline in Dermatology Life Quality Index (DLQI) Score
DLQI is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. Each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).
Time frame: Weeks 3, 7, 11, 15
Mean Change From Baseline in Itch Numerical Rating Scale (INRS) Score
The Itch NRS is a self-administered subject reported outcome questionnaire that is completed during protocol specified clinic visits. Participants indicate itch severity by circling the integer that best describes the worst level of itching due to psoriasis in the past 24 h on an 11-point scale anchored at 0, representing 'no itching' and 10, representing 'worst itch imaginable'.
Time frame: Weeks 3 and 15
Change in Coronary Artery Inflammation by CCTA
Change in coronary artery perivascular fat attenuation index (FAI) measured by coronary computed tomographic angiography (CCTA) as report in FAI-Score. \- Fat Attenuation Index score is a standardized measurement of coronary inflammation for each coronary artery (adjusted for age, sex as well as technical, biological, and anatomical characteristics) to allow individualized interpretation of the degree of coronary inflammation. FAI-Score range from 0-100. Higher FAI-Score means more inflammation. \- CaRi-Heart® Risk Score provides an individualized absolute risk of a fatal cardiac event within the next 8 years, incorporating: 1. Inflammation measured by FAI-Score 2. Plaque burden 3. Other clinical risk factors. CaRi-Heart Risk Score range from 0-100. It's a percentage that categorizes risk into three levels: Low (≤5%), Medium (5-10%), and High (\>10%). Higher CaRi-Heart Risk Score means higher risk. We reported the change in FAI Score and CaRi-Heart Risk Score from baseline here.
Time frame: 106 days (Week 15)
Change in Coronary Artery Plaque Burden by CCTA
Change in total, noncalcified and low attenuation coronary artery plaque volume some measurements have inter-quartile of 0 and median of 0 because most of the participants have a baseline value of 0 (no plaque at baseline) and remain no changes during the trial.
Time frame: 106 days (Week 15)
The trial was conducted at 21 clinical sites in the United States.
| Milestone | Active Treatment | Placebo |
|---|---|---|
| Started | 52 | 25 |
| Completed | 40 | 20 |
| Not completed | 12 | 5 |
| Withdrew: Lost to follow-up | 5 | 1 |
| Withdrew: Withdrawal by subject | 5 | 4 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Covid 19 infection | 1 | 0 |
PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)
| Percentage change of score | Active Treatment | Placebo |
|---|---|---|
| Mean Percent Change From Baseline in Psoriasis Area Severity Index (PASI) | -25.45 ± 26.552 | -18.95 ± 25.165 |
Percentage of participants achieving treatment success (clear =0 or almost clear =1) and greater than or equal to (\>=) 2 Point Improvement at Week 15 on the sIGA scale
| Participants | Active Treatment | Placebo |
|---|---|---|
| Percentage of Participants Achieving Treatment Success by the 5-point Static Investigator's Global Assessment Modified 2011 Version (sIGA) Score | 1 ± 0.59 | 1 ± 0.75 |
PASI combines the assessment of the severity of lesions and the area affected into a single score in the range 0 (no disease) to 72 (maximal disease)
| PASI score % change | Active Treatment | Placebo |
|---|---|---|
| Week 1 | -3.46 ± 9.757 | -1.24 ± 7.099 |
| Week 3 | -12.94 ± 18.529 | -8.28 ± 9.206 |
| week 7 | -20.14 ± 21.340 | -5.47 ± 15.341 |
| Week 11 | -22.50 ± 23.844 | -14.34 ± 17.159 |
PASI75 is a 75 percent reduction in PASI score. PASI50 is a 50 percent reduction in PASI score
| Participants | Active Treatment | Placebo |
|---|---|---|
| Week 1 - PASI 50 — Achieved | 0 | 0 |
| Week 1 - PASI 50 — Not achieved | 51 | 24 |
| Week 1 - PASI 75 — Achieved | 0 | 0 |
| Week 1 - PASI 75 — Not achieved | 51 | 24 |
| Week 3 - PASI 50 — Achieved | 2 | 0 |
| Week 3 - PASI 50 — Not achieved | 46 | 21 |
| Week 3 - PASI 75 — Achieved | 2 | 0 |
| Week 3 - PASI 75 — Not achieved | 46 | 21 |
| Week 7 - PASI 50 — Achieved | 5 | 0 |
| Week 7 - PASI 50 — Not achieved | 40 | 22 |
| Week 7 - PASI 75 — Achieved | 1 | 0 |
| Week 7 - PASI 75 — Not achieved | 44 | 22 |
| Week 11 - PASI 50 — Achieved | 5 | 0 |
| Week 11 - PASI 50 — Not achieved | 39 | 21 |
| Week 11 - PASI 75 — Achieved | 2 | 0 |
| Week 11 - PASI 75 — Not achieved | 42 | 21 |
Minimum: 0 percent, Maximum: 100 percent. Higher percentage indicates more skin with psoriasis.
| percentage change of body surface | Active Treatment | Placebo |
|---|---|---|
| Week 1 | -1.02 ± 6.045 | -1.93 ± 5.087 |
| Week 3 | -6.85 ± 18.220 | -6.88 ± 10.516 |
| Week 7 | -13.51 ± 22.010 | -0.66 ± 20.653 |
| Week 11 | -14.34 ± 22.567 | -4.99 ± 39.048 |
| Week 15 | -15.49 ± 27.099 | -6.55 ± 37.072 |
DLQI is a ten-question questionnaire used to measure the impact of skin disease on the quality of life of an affected person. Each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).
| score | Active Treatment | Placebo |
|---|---|---|
| Week 3 | -3.6 ± 4.01 | -2.0 ± 4.07 |
| Week 7 | -3.5 ± 4.39 | -2.2 ± 4.21 |
| Week 11 | -3.8 ± 4.20 | -2.8 ± 4.93 |
| Week 15 | -4.1 ± 4.5 | -2.7 ± 5.19 |
The Itch NRS is a self-administered subject reported outcome questionnaire that is completed during protocol specified clinic visits. Participants indicate itch severity by circling the integer that best describes the worst level of itching due to psoriasis in the past 24 h on an 11-point scale anchored at 0, representing 'no itching' and 10, representing 'worst itch imaginable'.
| scores on a scale | Active Treatment | Placebo |
|---|---|---|
| Week 3 | 6.2 ± 2.55 | 6.7 ± 2.13 |
| Week 15 | 6.1 ± 2.71 | 7.1 ± 2.59 |
Change in coronary artery perivascular fat attenuation index (FAI) measured by coronary computed tomographic angiography (CCTA) as report in FAI-Score. \- Fat Attenuation Index score is a standardized measurement of coronary inflammation for each coronary artery (adjusted for age, sex as well as technical, biological, and anatomical characteristics) to allow individualized interpretation of the degree of coronary inflammation. FAI-Score range from 0-100. Higher FAI-Score means more inflammation. \- CaRi-Heart® Risk Score provides an individualized absolute risk of a fatal cardiac event within the next 8 years, incorporating: 1. Inflammation measured by FAI-Score 2. Plaque burden 3. Other clinical risk factors. CaRi-Heart Risk Score range from 0-100. It's a percentage that categorizes risk into three levels: Low (≤5%), Medium (5-10%), and High (\>10%). Higher CaRi-Heart Risk Score means higher risk. We reported the change in FAI Score and CaRi-Heart Risk Score from baseline here.
| scores on a scale | Active Treatment | Placebo |
|---|---|---|
| CaRi-Heart Score | -2.34 ± 7.923 | 0.83 ± 4.393 |
| FAI Score - Left Anterior Descending Artery | 4.215 ± 3.0311 | 3.119 ± 1.7936 |
| FAI Score - Left Circumflex Coronary Artery | -0.808 ± 2.2185 | 0.332 ± 1.5630 |
| FAI Score - Right Coronary Artery | -2.288 ± 6.5015 | 0.022 ± 2.5323 |
Change in total, noncalcified and low attenuation coronary artery plaque volume some measurements have inter-quartile of 0 and median of 0 because most of the participants have a baseline value of 0 (no plaque at baseline) and remain no changes during the trial.
| cubic millimeter | Active Treatment | Placebo |
|---|---|---|
| Low attenuation plaque volume | 0 (0 to 0) | 0 (0 to 0.115) |
| Non-calcified plaque volume | 0.160 (0 to 1.280) | 0.320 (0 to 10.255) |
| Total plaque volume | 1.160 (0 to 5.310) | 1.535 (0 to 23.955) |
Collected over From enrollment until end of follow-up, up to 15 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Treatment | 0/52 (0%) | 2/52 (3.8%) | 4/52 (7.7%) |
| Placebo | 0/25 (0%) | 0/25 (0%) | 5/25 (20%) |
| Event | Active Treatment | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 1/52 | 0/25 |
| Bone abscessInfections and infestations | 1/52 | 0/25 |
| Event | Active Treatment | Placebo |
|---|---|---|
| Covid-19 infectionInfections and infestations | 1/52 | 3/25 |
| HeadacheNervous system disorders | 3/52 | 2/25 |
Intent-to-treat (ITT) analysis population included all randomized participants.
| Age, Continuous(years) | Active Treatment | Placebo | Total |
|---|---|---|---|
| Mean | 52 ± 10.6 | 50.5 ± 9.8 | 51.5 ± 10.3 |
| Sex: Female, Male(Participants) | Active Treatment | Placebo | Total |
|---|---|---|---|
| Female | 20 | 13 | 33 |
| Male | 32 | 12 | 44 |
| Ethnicity (NIH/OMB)(Participants) | Active Treatment | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 31 | 18 | 49 |
| Not Hispanic or Latino | 21 | 7 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Active Treatment | Placebo | Total |
|---|---|---|---|
| White | 48 | 23 | 71 |
| Black | 3 | 0 | 3 |
| Asian | 1 | 1 | 2 |
| American Native | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2021 to primary completion in Nov 2022, 16 months.
Results were first posted in May 2026, 3 years 6 months after primary completion.
Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 16 months is above that.
Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MLDL1278A
Abcentra